Home > Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? ? Comment on Br J Anaesth

Eagleton, Marie ORCID: https://orcid.org/0000-0002-4347-8122, Stokes, Siobhán ORCID: https://orcid.org/0000-0003-2406-0879, Fenton, Fiona ORCID: https://orcid.org/0000-0001-6187-974X and Keenan, Eamon ORCID: https://orcid.org/0000-0002-3395-3831 (2020) Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? ? Comment on Br J Anaesth. British Journal of Anaesthesia, 125, e382-e383. https://doi.org/10.1016/j.bja.2020.11.027.

External website: https://www.sciencedirect.com/science/article/pii/...


Editor -

A recent letter acknowledged the perceived clinical vulnerability to SARS-CoV-2 infection of groups chronically treated with or using opioids but noted there was little published clinical data to support this prediction1. Other international reports have described an unexpectedly low incidence of COVID-19 in people who misuse drugs.2 In Ireland, a rapid response to the pandemic was introduced to ensure that those already treated with opioid substitution treatment could continue and that those who were newly identified with opioid use disorder were rapidly inducted onto opioid substitution treatment (methadone or buprenorphine). 

[Click on the link above to read the full text]

Repository Staff Only: item control page